Skip to main content

bbo-10203

Generic: RAS/PI3K-alpha Interaction Inhibitor BBO-10203·Code: BBO-10203

bbo-10203: 3 clinical trials tracked.

bbo-10203 evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about bbo-10203, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 1 study sponsors
Clinical Trials (3)

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers

NCT06917079·Phase 1·BBOT
Recruiting

Primary endpoint: Incidence and severity of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)

Interventionalopen665 targetStarted 2025-03Completion 2029-0917 sites · Australia, United StatesTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

NCT06625775·Phase 1·BBOT
Recruiting

Primary endpoint: Determination of maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BBO-10203 as a single agent

Interventionalopen392 targetStarted 2024-10Completion 2028-1140 sites · Australia, Brazil, France, Spain…TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study

NCT06343402·Phase 1·BBOT
Recruiting

Primary endpoint: Adverse Events

Interventionalopen350 targetStarted 2024-05Completion 2031-0935 sites · Australia, Canada, Denmark, Spain…TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)